DarioHealth Presents New Research Demonstrating the Impact of a Digital Solution on Depression and Anxiety at the American Psychological Association Annual Convention
Aug 4, 2022
The studies underscore the value of Dario's integrated behavioral health solution to help more people connect to effective care that is right for their needs
NEW YORK, Aug. 4, 2022 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced today new research presented at the American Psychological Association ("APA") Annual Convention being held August 4th to 6th, 2022 in Minneapolis, Minnesota and virtually.
People living with chronic conditions are 2 to 3 times more likely to experience depression or anxiety than those living without a chronic illness, and untreated depression or anxiety often leads to poor health outcomes. Dario's unified digital therapeutics platform ensures that people with depression or anxiety, especially those living with chronic illnesses, are able to connect with convenient and effective care that contributes to improving their health.
The latest research from Dario examined the impact of a digital behavioral health solution for people living with clinically elevated levels of depression. The research findings demonstrated a wide-scale impact, with 72% of users reducing their symptoms of depression during 12 weeks of participation. Moreover, 44% of users in the study experienced clinically significant reductions in their levels of depression during the same timeframe.
In an additional study conducted by Dario, it was observed that 68% of people living with severe or moderate anxiety improved their symptoms following 12 weeks of utilizing the platform, and 40% of members with severe levels of anxiety experienced a clinically significant reduction during the evaluation period.
"Depression, anxiety and chronic conditions have a complicated and bidirectional relationship, making it critical to ensure Dario members are receiving the care they need to help manage both. Our latest studies provide further evidence that our solutions provide members with the care they need to help improve their overall health with effective, convenient digital tools," said Yifat Hershcovitz, PhD., Vice President of Clinical and Scientific Affairs at Dario and supervisor of the studies.
"Treatment for depression and anxiety in people with chronic conditions are known to be predictors of better overall health. Dario approaches this problem with a whole health, integrated solution for chronic condition management, and we are proud to see that this is making a difference for our members," said Omar Manejwala, MD, Chief Medical Officer at Dario.
You can learn more about the APA Convention by visiting their website at https://convention.apa.org.
About DarioHealth Corp.
DarioHealth Corp. (NASDAQ:DRIO) is a leading digital therapeutics (DTx) company revolutionizing how people with chronic conditions manage their health through a user-centric multi-chronic condition platform. Our platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health.
Our user-centric platform offers people continuous and customized care for health, disrupting the traditional episodic approach to healthcare. This approach empowers people to holistically adapt their lifestyles for sustainable behavior change, driving exceptional user satisfaction, retention, and results. Making the right thing to do the easy thing to do.
Dario provides its highly user rated solutions globally to health plans and other payors, self-insured employers, providers of care and directly to consumers. To learn more about DarioHealth and its digital health solutions, or for more information, visit http://dariohealth.com.
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and partners of DarioHealth Corp. related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. For example, the Company is using forward-looking statements in this press release when it discusses the potential benefits that may be realized by users utilizing the Dario platform. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™ as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
DarioHealth Corporate Contact
SOURCE DarioHealth Corp.